Develops drugs for cancers and viral diseases.
Jun 2026Revenue $95.0K/yrExpenses $11.2M/yr
No trendCash runway ≈ 8 months from Jun 2026
Figures by year
When will AIM ImmunoTech be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $95.0K and expenses $11.2M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $88.0K | $11.8M | −$11.7M |
| Dec 2024 | $170K | $19.9M | −$19.8M |
| Dec 2023 | $202K | $32.1M | −$31.9M |
| Dec 2022 | $141K | $20.1M | −$19.9M |
| Dec 2021 | $135K | $19.0M | −$18.8M |
| Dec 2020 | $163K | $15.3M | −$15.2M |
| Dec 2019 | $140K | $12.6M | −$12.4M |
| Dec 2018 | $367K | $11.9M | −$11.5M |
| Dec 2017 | $437K | $11.9M | −$11.4M |
| Dec 2016 | $92.0K | $13.9M | −$13.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.